Bone marrow transplant suppresses AIDS in patient

BERLIN (Reuters) - A bone marrow transplant using stem cells from a donor with natural genetic resistance to the AIDS virus has left an HIV patient free of infection for nearly two years, German researchers.

The patient, an American living in Berlin, was infected with the human immunodeficiency virus that causes AIDS and also had leukemia. The best treatment for the leukemia was a bone marrow transplant, which takes the stem cells from a healthy donor’s immune system to replace the patient’s cancer-ridden cells.

Dr. Gero Hutter and Thomas Schneider of the Clinic for Gastroenterology, Infections and Rheumatology of the Berlin Charite hospital said on Wednesday the team sought a bone marrow donor who had a genetic mutation known to help the body resist AIDS infection.

The mutation affects a receptor, a cellular doorway, called CCR5 that the AIDS virus uses to get into the cells it infects.

When they found a donor with the mutation, they used that bone marrow to treat the patient. Not only did the leukemia disappear, but so did the HIV.

“As of today, more than 20 months after the successful transplant, no HIV can be detected in the patient,” the clinic said in a statement.

“We performed all tests, not only with blood but also with other reservoirs,” Schneider told a news conference.

“But we cannot exclude the possibility that it’s still there.”

The researchers stressed that this would never become a standard treatment for HIV. Bone marrow stem cell transplants are rigorous and dangerous and require the patient to first have his or her own bone marrow completely destroyed.

Patients risk death from even the most minor infections because they have no immune system until the stem cells can grow and replace their own.

HIV has no cure and is always fatal. Cocktails of drugs can keep the virus suppressed, sometimes to undetectable levels. But research shows the virus never disappears — it lurks in so-called reservoirs throughout the body.

Hutter’s team said they have been unable to find any trace of the virus in their 42-year-old patient, who remains unnamed, but that does not mean it is not there.

“The virus is tricky. It can always return,” Hutter said.

The CCR5 mutation is found in about 3 percent of Europeans, the researchers said. They said the study suggests that gene therapy, a highly experimental technology, might someday be used to help treat patients with HIV.

(Reporting by Oliver Denzer; Writing by Maggie Fox in Washington; Editing by Vicki Allen)


Related Posts:

By Michael Kahn LONDON (Reuters) - A Colombian woman has received the world’s first tailor-made trachea transplant, grown by seeding a donor organ with her own stem cells to prevent her body rejecting it, an international research team reported on Wednesday. The success of the operation, performed in June using tissue generated from the woman’s own bone

Full Post: Woman gets first trachea transplant without drugs

By Julie Steenhuysen CHICAGO (Reuters) - Leukemia cells use powerful chemical signals to lure healthy blood-forming stem cells into their cancerous lairs, where they lose their power to make healthy blood cells, U.S. researchers said on Thursday. But by jamming these signals in mice, the team was able to protect the stem cells, called hematopoietic progenitor cells. If

Full Post: Fatal attraction: How leukemia seduces blood cells

By Will Dunham WASHINGTON (Reuters) - Men and women who get heart transplants are more likely to die when the donor was of the opposite sex, U.S. researchers said on Wednesday. The cause is not clear but could be due to size differences in the heart — men’s tend to be larger — or certain hormonal and

Full Post: Risks seen in opposite-sex heart transplants

By Michael Kahn LONDON (Reuters) - Doctors may one day be able to use stem cells taken from umbilical cord blood to build new heart valves for children born with heart defects, German scientists said on Monday. These valves could grow as a child develops, doing away with any need for repeated operations to replace outgrown artificial

Full Post: Umbilical cord blood may help build heart valves

By Michael Kahn LONDON (Reuters) - A novel drug combination using Genzyme Corp’s Mozobil shows it may be possible to spur bone marrow into releasing extra adult stem cells into the bloodstream to repair the heart and broken bones, researchers said on Thursday. The study of mice raises hope that researchers could use the same technique to

Full Post: New drug combo may boost stem cell production

Site Navigation

Most Read